Observational studyBMC pharmacology & toxicology2021
Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
Observational study in BMC pharmacology & toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis.BMC pharmacology & toxicology · 2022Pooled it
- Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: A systematic review and meta-analysis.British journal of clinical pharmacology · 2022Pooled it
- Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies.Clinical pharmacokinetics · 2026Article
- Linezolid Related Adverse Effects in Different Populations: A Review.Current drug safety · 2026Review
- Prediction model of thrombocytopenia on patients using linezolid: a ranked-based covariate selection with multi-center data.Frontiers in pharmacology · 2026Article
- Renal function affects the plasma concentration and hematological toxicity of linezolid in elderly patients: a propensity-matched cohort analysis.BMC geriatrics · 2025Article
- High accumulation of linezolid and its major metabolite in the serum of patients with hepatic and renal dysfunction is significantly associated with thrombocytopenia and anemia.Microbiology spectrum · 2025Article
- Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion.Antimicrobial agents and chemotherapy · 2025Article
- Exploring the impact of baseline platelet count on linezolid-induced thrombocytopenia: a retrospective single-center observation study.International journal of clinical pharmacy · 2025Observational
- Physiologically Based Pharmacokinetic Modeling and Dose Optimization of Linezolid in Pediatric Patients With Renal Impairment.Drug design, development and therapy · 2025Article
- The protective role of vitamin C against linezolid-induced hepato-renal toxicity in a rat model.Frontiers in pharmacology · 2025Article
- A nomogram incorporating linezolid and metabolite concentrations for predicting linezolid induced thrombocytopenia in patients with renal impairment.Scientific reports · 2024Article
- Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study.The Journal of antimicrobial chemotherapy · 2024Article
- Predictive Modeling of Drug-Related Adverse Events with Real-World Data: A Case Study of Linezolid Hematologic Outcomes.Clinical pharmacology and therapeutics · 2024Article
- Linezolid-Induced Thrombocytopenia in Patients with Renal Impairment: A Case Series, Review and Dose Advice.Drugs in R&D · 2024Review
- Linezolid induced hypoglycemia and anemia: A case report.Clinical case reports · 2023Article
- Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2023Review
- Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopenia.European journal of clinical pharmacology · 2023Article
- Renal replacement therapy and concurrent fluconazole therapy increase linezolid-related thrombocytopenia among adult patients.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLinezolid is administered as a fixed dose to all patients despite evidence of overexposure and thrombocytopenia in renal impairment. The aims of this study were to evaluate the risk of thrombocytopenia and the utility of therapeutic drug monitoring (TDM), and to propose alternate dosing regimens in patients with renal impairment.
methodsWe retrospectively reviewed patients ≥13 years old for whom serum linezolid trough concentration (C
resultsIn the 108 patients examined by multivariable analyses, renal impairment was independently associated with increased risk of thrombocytopenia (OR 3.17, 95%CI 1.10-9.12) and higher C
conclusionsEmpirical dose reduction to 300 mg every 12 h after administration of the initial fixed dose for 2 days and C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.